Oncology Channel
NSCLC
Search
Selected Topic
MD /Alert Exclusive
Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC
Watch Now
MD /Alert Exclusive
Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer
Watch Now
MD /Alert Exclusive
Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC
Watch Now
MD /Alert Exclusive
No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation
Watch Now
Recommended
5:20
American Society for Radiation Oncology
Radiation after Immunotherapy Improves PFS in NSCLC
2:28
MD /Alert Exclusive
FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment
1:29
MD /Alert Exclusive
Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC
3:25
MD /Alert Exclusive
The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC
3:16
MD /Alert Exclusive
Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC
5:09
MD /Alert Exclusive
ESMO Updates Clinical Practice Guidelines for SCLC
3:58
MD /Alert Exclusive
New Guidelines for Immunotherapy Use in Lung Cancer
1:30
MD /Alert Exclusive
FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment
3:10
MD /Alert Exclusive
Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC
2:58
MD /Alert Exclusive
Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC
1:28
MD /Alert Exclusive
FDA Grants Breakthrough Device Designations for MRD Test
2:46
MD /Alert Exclusive
CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC
1:57
MD /Alert Exclusive
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
1:19
MD /Alert Exclusive
FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression
3:46
MD /Alert Exclusive
Guideline Update in Stage IV NSCLC with Driver Alterations
1:40
MD /Alert Exclusive
Nivolumab Loses Small Cell Lung Cancer Indication
1:34
MD /Alert Exclusive
FDA Approves New Dosing for Durvalumab as NSCLC Treatment
1:47
MD /Alert Exclusive
FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC
1:50
MD /Alert Exclusive
FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC
2:13
MD /Alert Exclusive
FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients
2:03
MD /Alert Exclusive
New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans
1:45
MD /Alert Exclusive
NSCLC Diagnostic Test Speed Improved by New Automated Algorithm
5:07
MD /Alert Exclusive
ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment
1:49
MD /Alert Exclusive
Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement
4:08
MD /Alert Exclusive
Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective
2:00
MD /Alert Exclusive
Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC
2:45
MD /Alert Exclusive
New Combination Therapy Reaches Primary Endpoint in NSCLC Trial
2:30
MD /Alert Exclusive
Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo
1:29
Salk Institute
Two New Targets Discovered for NSCLC Treatments
3:00
MD /Alert Exclusive
Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC
7:34
National Comprehensive Cancer Network
NCCN Update on Systemic Therapies for Lung Cancer
MD /alert Exclusives
2:37
MD /Alert Exclusive
Antitumor Activity of HER2-Targeted Therapy in Patients with HER2-Mutant NSCLC
1:47
MD /Alert Exclusive
Targeted Radiation Extends Progression-Free Survival in Advanced Lung Cancer
1:50
MD /Alert Exclusive
Age Not a Factor in Survival Benefit with Immune Checkpoint Inhibitors for NSCLC
2:53
MD /Alert Exclusive
No Survival Benefit in NSCLC with Metformin in Concurrent Chemoradiation
1:29
MD /Alert Exclusive
Immunotherapy Bests Surgery, Adjuvant Chemo in NSCLC
3:25
MD /Alert Exclusive
The Importance of Pembrolizumab in First-Line Treatment of Metastatic NSCLC
3:16
MD /Alert Exclusive
Combination Ipilimumab, Pembrolizumab Linked to Greater Toxicity in Metastatic NSCLC
5:09
MD /Alert Exclusive
ESMO Updates Clinical Practice Guidelines for SCLC
3:58
MD /Alert Exclusive
New Guidelines for Immunotherapy Use in Lung Cancer
1:30
MD /Alert Exclusive
FDA Grants Breakthrough Therapy Designation for NSCLC KRAS Mutation Treatment
3:10
MD /Alert Exclusive
Sotorasib Beneficial in Subgroups of Patients with Pretreated KRAS p.G12C Mutated NSCLC
2:58
MD /Alert Exclusive
Chemo-IO May Improve Efficacy Outcomes in Patients with NSCLC
1:28
MD /Alert Exclusive
FDA Grants Breakthrough Device Designations for MRD Test
2:46
MD /Alert Exclusive
CheckMate-816 Trial Shows Benefits of Nivolumab, Chemo in NSCLC
1:57
MD /Alert Exclusive
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
1:19
MD /Alert Exclusive
FDA Approves Cemiplimab-rwlc for NSCLC with High PD-L1 Expression
3:46
MD /Alert Exclusive
Guideline Update in Stage IV NSCLC with Driver Alterations
1:40
MD /Alert Exclusive
Nivolumab Loses Small Cell Lung Cancer Indication
1:34
MD /Alert Exclusive
FDA Approves New Dosing for Durvalumab as NSCLC Treatment
1:34
MD /Alert Exclusive
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
1:54
MD /Alert Exclusive
Investigational KRAS G12C Inhibitor Shows Positive Phase 2 Results in NSCLC
1:47
MD /Alert Exclusive
FDA Approves Pralsetinib for Adults with Metastatic RET Fusion-Positive NSCLC
1:30
MD /Alert Exclusive
FDA Grants Priority Review for Fixed Dose Durvalumab
1:50
MD /Alert Exclusive
FDA Grants Osimertinib Breakthrough Therapy Designation for EGFR NSCLC
2:13
MD /Alert Exclusive
FDA Approves Brigatinib as First-Line Lung Cancer Treatment in ALK+ Patients
2:03
MD /Alert Exclusive
New USPSTF Lung Cancer Screening Recommendations Increase Eligibility in Women and African Americans
1:45
MD /Alert Exclusive
NSCLC Diagnostic Test Speed Improved by New Automated Algorithm
5:07
MD /Alert Exclusive
ASCO 2020: Clinical Trial Shows Safety and Efficacy for Stage 3 NSCLC Treatment
1:49
MD /Alert Exclusive
Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement
4:08
MD /Alert Exclusive
Pembrolizumab with Simultaneous Chemoradiotherapy Proves Safe and Effective
2:00
MD /Alert Exclusive
Investigational Agent Granted FDA Breakthrough Therapy Designation For NSCLC
2:45
MD /Alert Exclusive
New Combination Therapy Reaches Primary Endpoint in NSCLC Trial
2:30
MD /Alert Exclusive
Novel Anti-PD-1 Inhibitor Improves NSCLC PFS in Combo With Chemo
3:00
MD /Alert Exclusive
Anti PD-L1 Therapy Improves Long-Term Survival in Advanced NSCLC
2:28
MD /Alert Exclusive
FDA Grants Priority Review for Novel RET-Targeted NSCLC Treatment
Breaking Research
5:20
American Society for Radiation Oncology
Radiation after Immunotherapy Improves PFS in NSCLC
0:29
MUSC Hollings Cancer Center
Failure of First-line Cancer Treatment as a Result of Smoking
1:29
Salk Institute
Two New Targets Discovered for NSCLC Treatments
Featured NSCLC Videos
5:23
Medscape
Immunotherapy's Expanding Indications: ImmunoPlus
6:08
Medscape
Immunotherapy's Expanding Indications: Standard Shift
Curated For You
24:43
Yale Cancer Center Grand Rounds
Radiation Induces Systemic Immune Response in NSCLC
7:34
National Comprehensive Cancer Network
NCCN Update on Systemic Therapies for Lung Cancer
2:00
Springer Healthcare IME
Upcoming Second-Line NSCLC Treatments